

Attorney Docket No.: **RTS-0239**  
Inventors: **Monia et al.**  
Serial No.: **10/002,491**  
Filing Date: **November 15, 2001**  
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (original): A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding human FXR, wherein said compound specifically hybridizes with said nucleic acid molecule encoding human FXR and inhibits the expression of human FXR.

Claim 2 (original): The compound of claim 1 which is an antisense oligonucleotide.

Claim 3 (canceled)

Claim 4 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 5 (original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 6 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (original): The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Attorney Docket No.: **RTS-0239**  
Inventors: **Monia et al.**  
Serial No.: **10/002,491**  
Filing Date: **November 15, 2001**  
Page 3

Claim 8 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (original): A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding human FXR.

Claim 12 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Claim 15 (original): A method of inhibiting the expression of human FXR in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of human FXR is inhibited.

Attorney Docket No.: **RTS-0239**  
Inventors: **Monia et al.**  
Serial No.: **10/002,491**  
Filing Date: **November 15, 2001**  
Page 4

Claim 16 (original): A method of treating a human having a disease or condition associated with FXR comprising administering to said human a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of FXR is inhibited.

Claim 17 (original): The method of claim 16 wherein the disease or condition is a cardiovascular disease.

Claim 18 (original): The method of claim 16 wherein the disease or condition is atherosclerosis.

Claim 19 (original): The method of claim 16 wherein the disease or condition is characterized by hypercholesterolemia.

Claim 20 (original): The method of claim 16 wherein the disease or condition is characterized by increased levels of serum cholesterol.

---